These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Molecular profiling and companion diagnostics: where is personalized medicine in cancer heading? Verma M Per Med; 2014 Nov; 11(8):761-771. PubMed ID: 29764045 [TBL] [Abstract][Full Text] [Related]
5. [Clinical and health economic challenges of personalized medicine]. Brüggenjürgen B; Kornbluth L; Ferrara JV; Willich SN Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):710-4. PubMed ID: 22526860 [TBL] [Abstract][Full Text] [Related]
6. Payers and the assessment of clinical utility for companion diagnostics. Quinn B Clin Pharmacol Ther; 2010 Dec; 88(6):751-4. PubMed ID: 21081944 [TBL] [Abstract][Full Text] [Related]
7. Reflections on market access for personalized medicine: recommendations for Europe. Payne K; Annemans L Value Health; 2013; 16(6 Suppl):S32-8. PubMed ID: 24034310 [TBL] [Abstract][Full Text] [Related]
8. Advocacy in personalized medicine: a developing strength in a complex space. Miller I; Pothier K; Dunn M Per Med; 2010 Mar; 7(2):179-186. PubMed ID: 29783322 [TBL] [Abstract][Full Text] [Related]
9. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States. Frueh FW Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309 [TBL] [Abstract][Full Text] [Related]
10. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS. Cowling T; Boucher M Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717 [TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology, biomarkers and personalized medicine: education please. de Koning P; Keirns J Biomark Med; 2009 Dec; 3(6):685-700. PubMed ID: 20477707 [TBL] [Abstract][Full Text] [Related]
13. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. O'Donnell JC Value Health; 2013; 16(6 Suppl):S1-3. PubMed ID: 24034305 [TBL] [Abstract][Full Text] [Related]
14. Impact of Biomarkers on Personalized Medicine. Carrigan P; Krahn T Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258 [TBL] [Abstract][Full Text] [Related]
15. Translating pharmacogenomics into personalized medicine and drug development. Zhang W; Chan TY; Fan L; Guo Y; Zhou HH Per Med; 2012 Jan; 9(1):93-97. PubMed ID: 29783288 [TBL] [Abstract][Full Text] [Related]
16. Golden Helix Pharmacogenomics Days: educational activities on pharmacogenomics and personalized medicine. Squassina A; Severino G; Grech G; Fenech A; Borg J; Patrinos GP Pharmacogenomics; 2012 Apr; 13(5):525-8. PubMed ID: 22462744 [TBL] [Abstract][Full Text] [Related]
17. The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics. Trusheim MR; Berndt ER Drug Discov Today; 2015 Dec; 20(12):1439-50. PubMed ID: 26542060 [TBL] [Abstract][Full Text] [Related]
18. A perspective analysis: companion diagnostics: an evolving paradigm in 21st century healthcare. Kaufmann M; Keppens M; Blair ED Per Med; 2015 Aug; 12(4):389-402. PubMed ID: 29771658 [TBL] [Abstract][Full Text] [Related]
19. To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population. De Andrés F; Terán S; Hernández F; Terán E; LLerena A OMICS; 2016 Dec; 20(12):699-710. PubMed ID: 27849442 [TBL] [Abstract][Full Text] [Related]
20. Role of Proteomics in the Development of Personalized Medicine. Jain KK Adv Protein Chem Struct Biol; 2016; 102():41-52. PubMed ID: 26827601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]